On the Decline

Dec 22, 2009

The Wall Street Journal's Health Blog has put together a chart of R&D spending by US drug companies — a related article in the paper said that R&D fell in 2009 by 3.8 percent to $382.6 billion. Pfizer and Johnson and Johnson's spending dropped by 10.8 and 12.7 percent, respectively while the other companies showed gains in spending.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Stricter Vaccine Standards

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

Another Trial to Ramp Up

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Few Billion More

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

Genome Research Studies on SARS-CoV-2 Super-Spreaders, Pan-Cancer Epigenetics, More

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.

Menu

On the Decline

To read the full story....

Breaking News

Vela Diagnostics Receives Second FDA Emergency Use Authorization for SARS-CoV-2 Molecular Test

Centogene Reports 13 Percent Decline in Q2 Revenues

Metabolon Closes $72M in Debt and Equity Funding

Becton Dickinson Submits Premarket Approval Supplement to FDA for HPV Assay

Metastatic Cancer Treatment Markers Identified in Clinical WGS Study

Genome Sequencing Boosts Diagnostic Yield in Children With Unexplained Medical Complexity

The Scan

Stricter Vaccine Standards

Another Trial to Ramp Up

Few Billion More

Genome Research Studies on SARS-CoV-2 Super-Spreaders, Pan-Cancer Epigenetics, More

Sponsorships